Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06289582 · ClinicalTrials.gov registry record · Early Phase 1
Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)
A Early Phase 1 study of Parkinson Disease, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT06289582: Recruiting Early Phase 1 study of Parkinson Disease, sponsored by University of Alabama at Birmingham.
NCT06289582 is a Early Phase 1 study of Parkinson Disease that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 60 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06289582, a Early Phase 1 study of Parkinson Disease, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall goal of this protocol is to investigate \[18F\]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in \[18F\]DPA-714 binding in PD participants during a 24-month interval. Primary Objectives * To compare \[18F\]DPA-714 binding in prodromal and manifest PD and healthy volunteers. * To determine the longitudinal change in \[18F\]DPA-714 during a 24-month interval for prodromal and early initially untreated PD participants. Secondary Objectives * To evaluate the correlation between baseline \[18F\]DPA-714 and PPMI clinical and biomarker outcomes. * To evaluate the correlation between the longitudinal change of \[18F\]DPA-714 and PPMI clinical and biomarker outcomes * To acquire safety data following injection of \[18F\]DPA-714
Primary Outcome
The changes over time in neuroinflammation based on TSPO will be assessed by comparing TSPO-PET imaging at baseline, 12 months and 24 months after enrollment.
Conditions Studied
Interventions
- DRUG [F-18]DPA714 administration IV
Study Locations (1)
Alabama
- UAB - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2024-08-14 |
| Est. Completion | 2028-06 |
| Phase | Early Phase 1 |
What NCT06289582 shows while recruiting
NCT06289582 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which [F-18]DPA714 administration IV is the first listed.
NCT06289582 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT06289582 about?
NCT06289582 is a clinical study titled "Longitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging)". The overall goal of this protocol is to investigate \[18F\]DPA-714 binding in prodromal and early manifest Parkinson's Disease (PD) and to determine the baseline and change from baseline in \[18F\]DPA-714 binding in PD participants during a 24-month interval. Primary Objectives * To compare \[18F\...
What is the current status of trial NCT06289582?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 60 participants. The study started on 2024-08-14. Estimated completion is 2028-06.
What conditions does trial NCT06289582 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06289582?
The interventions under investigation include: [F-18]DPA714 administration IV (DRUG).
Who is sponsoring clinical trial NCT06289582?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06289582 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06289582's enrollment target sits among peer trials
60 125th of 297 higher than 154 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Midodrine vs Abdominal Compression on Cardiovascular Risk Markers in Autonomic Failure Patients
RECRUITING · Early Phase 1
-
Title: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G)
RECRUITING · Early Phase 1
-
Multiple Objective Particle Swarm Optimization Postural Instability Gait Disorder
RECRUITING · Early Phase 1
-
Noise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease
RECRUITING · Early Phase 1
-
Quantitative Imaging of Brain Glymphatic Function in Humans
ACTIVE NOT RECRUITING · Early Phase 1
-
Evaluation of Neuroinflammation in Parkinson's Disease Using 18F-NOS PET/CT
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
- NCT02114450 · 60 participants · NA
Human-Machine System for the H2 Lower Limb Exoskeleton
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI